Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
about
Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudineSuccessful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutantKASL clinical practice guidelines: management of chronic hepatitis BAntiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferonCurrent challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Early entecavir treatment for chronic hepatitis B with severe acute exacerbation.Optimization therapy for the treatment of chronic hepatitis BEarly viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis BEvaluation of the COBAS amplicor HBV monitor assay and comparison with the ultrasensitive HBV hybrid capture 2 assay for quantification of hepatitis B virus DNAManagement of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelinesVirologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis BUnsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutationsViral hepatitis in HIV infection.Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assayViral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis BDetection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients.Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy.A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B.Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24.52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis BEfficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strainsEarly hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B.Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective studyNew approaches in the management of chronic hepatitis B: role of tenofovir.Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysisHBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.HBV and HCV therapy.Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and SafetyEarly detection of hepatitis B drug resistance: implications for patient management.Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhoticsDelayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue TherapyImpact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patientsPretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovirKASL Clinical Practice Guidelines: Management of chronic hepatitis B.
P2860
Q24806372-EA54927D-A834-4374-967D-EFFB93F20DF7Q25256648-B2607F14-174C-4D26-AC34-B9D90FBDEA8DQ26752475-399DC9EA-E111-4EAC-BF12-4DD1119108A7Q26830435-53F26760-6247-4AB4-877B-EB4D67DB04B0Q30381336-6E520D1B-E62A-49AC-A820-9790337CE681Q30391932-217D3941-CA4A-4703-B8CD-BAA64219CD9CQ33623019-FE5493DF-7691-4959-AFD5-BC9C3E744C05Q33626813-C7F5AAC3-5B20-4E9B-A7B0-3AFAD5945FCEQ33676349-05013242-1E89-41A5-BD13-F8988A3A12C1Q33825842-C6AAB123-E484-4A75-9C71-10E7CDF9EEA5Q33855708-F2830ADA-CED1-49EB-B8D1-292C8878B8AEQ33918275-F822F70C-115F-41BF-8DBE-F125227EE4CDQ33940140-1493CABF-02FA-4557-9331-4D9CF406D142Q34086980-4E86300D-5ECD-4F6A-9C36-4D1C4A584FEBQ34200074-BB634EBA-F358-40D1-A9E9-66B1E52E0D1FQ34233156-EC21B5FB-86E3-4CB5-9904-0C8A5D6FC483Q34294342-11F9C5E5-5776-4490-BCD4-60A0E7DFAFA4Q34303163-7AE40378-07C8-49C7-9A14-F9BDD5A5EC20Q34494102-00C4B08D-E6E4-4091-AA70-5033DED0AA16Q34509494-4C77CAE5-1E8D-4A1C-821A-A1840DB17324Q34579911-0A562351-D3E3-4C74-B268-076F943D076DQ34596639-C71FC4CE-5E80-4213-9756-189B335A2C95Q34601513-8D3BFB5B-84A0-478A-97E8-D9E9DA5DE9CDQ34700034-E6901684-E7DF-41D0-8B68-6165A8759C95Q34735876-CB4AD336-7A23-41EB-92DF-913FD55B6BF1Q34959568-C4BBD963-D0DF-4A67-A6C0-8BF1B246EC56Q34974141-5C3BC144-B6C2-4958-A53F-A31ECE625319Q35026531-755167E4-59FC-478D-A669-495C537B9406Q35132805-63F6B90E-FD70-4797-8A72-602DD3C21288Q35224111-D075EEDA-50A4-45AB-8C3B-9FC751303504Q35231813-7743C50D-07D2-4E2D-8346-5684FABBD167Q35259824-93D8C491-CEE9-4B60-843B-C12059A7D2F0Q35535861-4F7D3AFE-4CCF-48E1-B384-042B0EF037A6Q35543876-6C6C79F1-4776-460E-ACE2-F53B12FD55ECQ35615890-CA870E36-7BD9-4734-B9B2-D14D577B44A3Q35635522-B151EEEE-B40C-4104-9333-B272181AA6E2Q35824075-6EA38149-FB63-4A1D-A19A-89C371A22143Q35833216-6F6BA45F-CC59-4EF5-B010-9E24FFA63C91Q36018658-1C20AEE4-348A-47FD-AD55-A4B2E39E1573Q36153966-E5EEEAE2-79DF-4328-82FE-D97B2F48B889
P2860
Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Factors associated with hepati ...... prolonged lamivudine therapy.
@en
Factors associated with hepati ...... prolonged lamivudine therapy.
@nl
type
label
Factors associated with hepati ...... prolonged lamivudine therapy.
@en
Factors associated with hepati ...... prolonged lamivudine therapy.
@nl
prefLabel
Factors associated with hepati ...... prolonged lamivudine therapy.
@en
Factors associated with hepati ...... prolonged lamivudine therapy.
@nl
P2093
P356
P1433
P1476
Factors associated with hepati ...... g prolonged lamivudine therapy
@en
P2093
P304
P356
10.1053/JHEP.2001.27563
P407
P433
P577
2001-10-01T00:00:00Z